Investigational Drug Information for Dovitinib
✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
What is the drug development status for Dovitinib?
Dovitinib is an investigational drug.
There have been 52 clinical trials for Dovitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Carcinoma, Adenoid Cystic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
Summary for Dovitinib
|US Patent Applications||2,598|
|WIPO Patent Applications||1,884|
|Japanese Patent Applications||851|
|Clinical Trial Progress||Phase 3 (2011-03-01)|
Recent Clinical Trials for Dovitinib
|Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors||Amarex Clinical Research||Phase 1|
|Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors||Allarity Therapeutics||Phase 1|
|Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma||Seoul National University Hospital||Phase 2|
Clinical Trial Summary for Dovitinib
Top disease conditions for Dovitinib
Top clinical trial sponsors for Dovitinib
US Patents for Dovitinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|